Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Leanne Gasink"'
Autor:
Vipul K. Gupta, Gina Patel, Leanne Gasink, Floni Bajraktari, Yang Lei, Akash Jain, Praveen Srivastava, Angela K. Talley
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 7, Pp 1654-1663 (2022)
Abstract Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) is a novel oral carbapenem prodrug of tebipenem (TBP), the active moiety, currently in development for treating serious bacterial infections. This study assessed the bioequivalence (BE) of the
Externí odkaz:
https://doaj.org/article/177fa87b6f764ad0b59fd6e0b18e5ec1
Autor:
Vipul K. Gupta, Gary Maier, Leanne Gasink, Amanda Ek, Mary Fudeman, Praveen Srivastava, Angela Talley
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral prodrug of pharmacologically active moiety tebipenem (TBP), which is a carbapenem with activity against multidrug-resistant Gram-negative pathogens. Conversion from the prodrug to the active moie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30e89c4cd6edc79ab99aa97cd3b4788a
https://doi.org/10.1128/aac.01509-22
https://doi.org/10.1128/aac.01509-22
Autor:
Gina Patel, Vipul K. Gupta, Leanne Gasink, Floni Bajraktari, Yang Lei, Akash Jain, Praveen Srivastava, Angela K. Talley
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is a novel oral carbapenem prodrug being developed for the treatment of serious bacterial infections. This open-label, 3-period, fixed sequence study evaluated the effect of gastric acid-reducing agents, al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59b001dcc0e1d64414d26914a5743010
https://doi.org/10.1128/aac.01495-22
https://doi.org/10.1128/aac.01495-22
Autor:
Paul C McGovern, Florian Wagenlehner, Leanne Gasink, Greg Moeck, Patrick L McLeroth, Mary Beth, Aaron Dane, Tim Henkel
Publikováno v:
Open Forum Infectious Diseases. 9
Background Carbapenem-resistant Enterobacterales and multidrug resistant Pseudomonas aeruginosa are global antimicrobial resistance threats. Cefepime-taniborbactam (FTB) is an investigational β-lactam/ β-lactamase inhibitor combination that is acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::723ca35e57bb2a4899a5ba3baf454c7a
https://doi.org/10.1093/ofid/ofac492.022
https://doi.org/10.1093/ofid/ofac492.022
Autor:
Gina Patel, Keith A. Rodvold, Vipul K. Gupta, Jon Bruss, Leanne Gasink, Floni Bajraktari, Yang Lei, Akash Jain, Praveen Srivastava, Angela K. Talley
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug antimicrobial agent with broad-spectrum activity that includes multidrug-resistant (MDR) Enterobacterales . This study evaluated the safety, tolerability, and pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b4e414d088b90d019506bbdeb97c12
https://doi.org/10.1128/aac.02407-21
https://doi.org/10.1128/aac.02407-21
Autor:
Vipul K Gupta, Gary Maier, Leanne Gasink, Amanda Ek, Mary Fudeman, Praveen Srivastava, Angela Talley
Publikováno v:
Open Forum Infectious Diseases
Background Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral prodrug that is converted to tebipenem (TBP), the active moiety, with activity against multidrug-resistant gram-negative pathogens, including extended-spectrum-β-lactamase (ESBL)-prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d87336c9e180baf3d2c794c4989a41b5
http://europepmc.org/articles/PMC8644141
http://europepmc.org/articles/PMC8644141
Autor:
Vipul K Gupta, Gina Patel, Leanne Gasink, Floni Bajraktari, Yang Lei, Akash Jain, Praveen Srivastava, Angela Talley
Publikováno v:
Open Forum Infectious Diseases. 8:S652-S652
Background Tebipenem-pivoxil-hydrobromide (TBP-PI-HBr) is a novel oral carbapenem being developed to treat serious bacterial infections including complicated urinary tract infection. The objectives of this study were to assess the bioequivalence (BE)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4470f9a3ab8d1971f155fa9da947d2d
https://doi.org/10.1093/ofid/ofab466.1314
https://doi.org/10.1093/ofid/ofab466.1314
Publikováno v:
Gastroenterology. 134:A-360
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cad3e506503b15b0ce9e69eb87b7beb0
https://doi.org/10.1016/s0016-5085(08)61681-9
https://doi.org/10.1016/s0016-5085(08)61681-9